Home
Search
Study Topics
Glossary
|
|
|
|
|
|
Sponsored by: |
National Institute on Drug Abuse (NIDA) |
---|---|
Information provided by: | National Institute on Drug Abuse (NIDA) |
ClinicalTrials.gov Identifier: | NCT00360191 |
The purpose of this study is to determine if buspirone combined with motivational enhancement therapy is effective in reducing marijuana use in marijuana-dependent adults.
Condition | Intervention | Phase |
---|---|---|
Marijuana Abuse |
Drug: Buspirone Procedure: Motivational enhancement therapy |
Phase II |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double-Blind, Placebo Control, Single Group Assignment, Safety/Efficacy Study |
Official Title: | A Placebo-Controlled Trial of Buspirone for Treatment of Marijuana Dependence |
Ages Eligible for Study: | 18 Years to 65 Years |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | Yes |
Inclusion Criteria:
Exclusion Criteria:
United States, South Carolina | |
Medical University of South Carolina | |
Charleston, South Carolina, United States, 29425 |
Principal Investigator: | Aimee L McRae, PharmD | Medical University of South Carolina |
Study ID Numbers: | K23DA015440, K23DA015440 |
Study First Received: | August 2, 2006 |
Last Updated: | December 11, 2007 |
ClinicalTrials.gov Identifier: | NCT00360191 |
Health Authority: | United States: Federal Government |
Buspirone Mental Disorders Substance-Related Disorders |
Disorders of Environmental Origin Marijuana Abuse Serotonin |
Serotonin Agonists Neurotransmitter Agents Tranquilizing Agents Serotonin Agents Molecular Mechanisms of Pharmacological Action Therapeutic Uses |
Physiological Effects of Drugs Psychotropic Drugs Central Nervous System Depressants Anti-Anxiety Agents Central Nervous System Agents Pharmacologic Actions |